Advertisement

Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?

  • Doan T. Ngo
    Affiliations
    Department of Pharmacy, University of South Australia, South Australia, Australia

    Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, Department of Medicine, The University of Adelaide, Australia
    Search for articles by this author
  • Aaron L. Sverdlov
    Affiliations
    Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, Department of Medicine, The University of Adelaide, Australia
    Search for articles by this author
  • John J. McNeil
    Affiliations
    Monash University, Department of Epidemiology and Preventive Medicine, Victoria, Australia
    Search for articles by this author
  • John D. Horowitz
    Correspondence
    Reprint requests should be addressed to John D. Horowitz, MBBS, PhD, Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, University of Adelaide, 28 Woodville Rd, Woodville South, South Australia, 5011
    Affiliations
    Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, Department of Medicine, The University of Adelaide, Australia
    Search for articles by this author

      Abstract

      Background

      Vitamin D deficiency is associated with significant increases in the incidence of cardiovascular risk factors and mortality. However, the mechanisms underlying this association remain unclear. The current study evaluated the possible relationships among vitamin D status, endothelial dysfunction, and inflammation.

      Methods

      Plasma concentrations of 25-hydroxyvitamin D3 were determined by radioimmunoassay in a normal population cohort (n=253) aged 51 to 77 years (mean 63.4±6 years). Asymmetric dimethylarginine, a marker/mediator of endothelial dysfunction, was assayed by high-performance liquid chromatography. High-sensitivity C-reactive protein levels were used as a marker of inflammatory activation.

      Results

      On univariate analyses, low 25-hydroxyvitamin D3 levels were inversely correlated with asymmetric dimethylarginine concentrations, high-sensitivity C-reactive protein levels, and body mass index. Seasonal fluctuations in 25-hydroxyvitamin D3 levels were associated with reciprocal asymmetric dimethylarginine concentration fluctuations. Hypertension and treatment with an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker also were associated with low 25-hydroxyvitamin D3 levels. On multiple linear analysis, both asymmetric dimethylarginine (β=−0.19, P=.003) and high-sensitivity C-reactive protein (β=−0.14, P=.03) concentrations were inversely correlated with plasma 25-hydroxyvitamin D3 concentrations; other significant correlates were male gender (β=0.19, P=.003), calcium levels (β=0.14, P=.03), and use of angiotensin-converting enzyme inhibitor (β=−0.17, P=.007).

      Conclusion

      Low 25-hydroxyvitamin D3 levels are associated with markers of endothelial dysfunction and inflammatory activation, representing potential mechanisms for incremental coronary risk.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hollick M.F.
        Vitamin D deficiency.
        N Engl J Med. 2007; 357: 266-281
        • Zitterman A.
        Vitamin D and disease prevention with special reference to cardiovascular disease.
        Prog Biophys Mol Biol. 2006; 92: 39-48
        • Veldman C.M.
        • Cantorna M.T.
        • DeLuca H.F.
        Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system.
        Arch Biochem Biophys. 2000; 374: 334-338
        • Bouillon R.
        • Carmeliet G.
        • Verlinden L.
        • et al.
        Vitamin D and human health: lessons from vitamin D receptor null mice.
        Endocr Rev. 2008; 29: 726-776
        • Lemmila S.
        • Saha H.
        • Virtanen V.
        • et al.
        Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis.
        Am J Nephrol. 1998; 18: 404-410
        • Wu J.
        • Garami M.
        • Cheng T.
        • Gardner D.G.
        1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes.
        J Clin Invest. 1996; 97: 1577-1588
        • Shoji T.
        • Shinohara K.
        • Kimoto E.
        • et al.
        Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population.
        Nephrol Dial Transplant. 2004; 19: 179-184
        • Scragg R.
        Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation.
        Int J Epidemiol. 1981; 10: 337-341
        • Zipes D.P.
        Warning: the short days of winter may be hazardous to your health.
        Circulation. 1999; 100: 1590-1592
        • Mortimer Jr, E.A.
        • Monson R.R.
        • MacMahon B.
        Reduction in mortality from coronary heart disease in men residing at high altitude.
        N Engl J Med. 1977; 296: 581-585
        • Fabsitz R.
        • Feinleib M.
        Geographic patterns in county mortality rates from cardiovascular diseases.
        Am J Epidemiol. 1980; 111: 315-328
        • Talmor Y.
        • Bernheim J.
        • Klein O.
        • et al.
        Calcitriol blunts pro-atherosclerotic parameters through NFkappa B and p38 in vitrol.
        Eur J Clin Invest. 2008; 38: 548-554
        • Aihara K.
        • Azuma H.
        • Akaike M.
        • et al.
        Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice.
        J Biol Chem. 2004; 279: 35798-35802
        • London G.M.
        • Guerin A.P.
        • Verbeke F.H.
        • et al.
        Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency.
        J Am Soc Nephrol. 2007; 18: 613-620
        • Sugden J.A.
        • Davies J.I.
        • Witham M.D.
        • et al.
        Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels.
        Diabet Med. 2008; 25: 320-325
        • Sydow K.
        • Munzel T.
        ADMA and oxidative stress.
        Atheroscler Suppl. 2003; 4: 41-51
        • Boger R.H.
        • Bode-Boger S.M.
        • Thiele W.
        • et al.
        Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.
        Circulation. 1997; 95: 2068-2074
        • Boger R.H.
        The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
        Cardiovasc Res. 2003; 59: 824-833
        • Sabatine M.S.
        • Morrow D.A.
        • Jablonski K.A.
        • et al.
        Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
        Circulation. 2007; 115: 1528-1536
        • Ridker P.M.
        The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?.
        Arterioscler Thromb Vasc Biol. 2008; 28: 1222-1224
        • Zoccali C.
        • Maas R.
        • Cutrupi S.
        • et al.
        Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections.
        Nephrol Dial Transplant. 2007; 22: 801-806
        • Grant J.F.
        • Chittleborough C.R.
        • Taylor A.W.
        • et al.
        The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases.
        Epidemiol Perspect Innov. 2006; 3: 4
        • Ngo D.T.
        • Sverdlov A.L.
        • Willoughby S.R.
        • et al.
        Determinants of occurrence of aortic sclerosis in an aging population.
        J Am Coll Cardiol Img. 2009; 2: 919-927
        • Devereux R.B.
        • Lutas E.M.
        • Casale P.N.
        • et al.
        Standardization of M-mode echocardiographic left ventricular anatomic measurements.
        J Am Coll Cardiol. 1984; 4: 1222-1230
        • McEniery C.M.
        • Wallace S.
        • Mackenzie I.S.
        • et al.
        Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans.
        Hypertension. 2006; 48: 602-608
        • Heresztyn T.
        • Worthley M.I.
        • Horowitz J.D.
        Determination of l-arginine and NG, NG - and NG, NG′ -dimethyl-L-arginine in plasma by liquid chromatography as AccQ-Fluor fluorescent derivatives.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 805: 325-329
        • Dobnig H.
        • Pilz S.
        • Scharnagl H.
        • et al.
        Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality.
        Arch Intern Med. 2008; 168: 1340-1349
        • Norman A.W.
        • Bouillon R.
        • Whiting S.J.
        • et al.
        13th Workshop consensus for vitamin D nutritional guidelines.
        J Steroid Biochem Mol Biol. 2007; 103: 204-205
        • Tai K.
        • Need A.G.
        • Horowitz M.
        • Chapman I.M.
        Vitamin D, glucose, insulin, and insulin sensitivity.
        Nutrition. 2008; 24: 279-285
        • Horowitz J.D.
        • Heresztyn T.
        An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 851: 42-50
        • Schnabel R.
        • Blankenberg S.
        • Lubos E.
        • et al.
        Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study.
        Circ Res. 2005; 97: e53-e59
        • Martins D.
        • Wolf M.
        • Pan D.
        • et al.
        Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey.
        Arch Intern Med. 2007; 167: 1159-1165
        • Wang T.J.
        • Pencina M.J.
        • Booth S.L.
        • et al.
        Vitamin D deficiency and risk of cardiovascular disease.
        Circulation. 2008; 117: 503-511
        • Giovannucci E.
        • Liu Y.
        • Hollis B.W.
        • Rimm E.B.
        25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study.
        Arch Intern Med. 2008; 168: 1174-1180
        • Valkonen V.P.
        • Paiva H.
        • Salonen J.T.
        • et al.
        Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.
        Lancet. 2001; 358: 2127-2128
        • Talmor Y.
        • Golan E.
        • Benchetrit S.
        • et al.
        Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells.
        Am J Physiol Renal Physiol. 2008; 294: F1059-F1064
        • Aihara K.
        • Azuma H.
        • Akaike M.
        • et al.
        Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice.
        J Biol Chem. 2004; 279: 35798-35802
        • London G.M.
        • Guerin A.P.
        • Verbeke F.H.
        • et al.
        Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency.
        J Am Soc Nephrol. 2007; 18: 613-620
        • Li Y.C.
        • Kong J.
        • Wei M.
        • et al.
        1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.
        J Clin Invest. 2002; 110: 229-238
        • Forman J.P.
        • Curhan G.C.
        • Taylor E.N.
        Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women.
        Hypertension. 2008; 52: 828-832
        • Cushman M.
        • Arnold A.M.
        • Psaty B.M.
        • et al.
        C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study.
        Circulation. 2005; 112: 25-31
        • Targher G.
        • Bertolini L.
        • Padovani R.
        • et al.
        Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients.
        Clin Endocrinol (Oxf). 2006; 65: 593-597